The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
Shareholders of Takeda Pharmaceutical on June 27 voted down a proposal calling for the addition of a “claw-back clause” to the company’s articles of incorporation, which would oblige its board members to return their pay when excessive investments result in…
To read the full story
Related Article
- Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Claw-Back Clause Thwarted, but Majority of Takeda Shareholders Voted in Favor
July 4, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
May 31, 2019
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…